Emerging Stocks Down Under 16 August 2022: Telix Pharmaceuticals (ASX:TLX)
Telix Pharmaceuticals: Hitting the Ground RunningThis week in Emerging Stocks Down Under we turn our attention to another Biotech that went on a run in the 18 months after the Corona Crash, then retreated but has risen again on the back of good news. Telix Pharmaceuticals (ASX: TLX), unlike Imugene (ASX: IMU), has finally got a product on the market, a prostate cancer imaging diagnostic called Illuccix. And its second quarter of sales saw a jump of roughly 10x. Click here to read the previous edition of Emerging Stocks Down Under published 9 August 2022. For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.
Please register or upgrade your plan to access this content.